Other languages Hemostemix Inc.

Equities

HEM

CA4236943060

Market Closed - Toronto S.E. Other stock markets 20:18:45 02/05/2024 BST			5-day change	1st Jan Change
0.04 ^CAD	+14.29%		-11.11%	-42.86%

04-30	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-06	Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences	02-06
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29
Hemostemix Inc. Announces That 4Th Heart Study Published in Stem Cell Research & Therapy Confirms Treatment for Heart Disease	31/10/23
Hemostemix Inc. Announces Its Study of NCP-01 Supporting Brain Computer Interfaces Has Been Submitted for Peer Review Publication	15/09/23
Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/08/23
Hemostemix Inc. Submits its Retrospective Heart Study to Leading Stem Cell Journal	10/08/23
Hemostemix Completes Private Placement; Down 4.2%	28/06/23
Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23
Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/05/23
Hemostemix Hiring Four Biotechnologists in Montreal, Says Applying for Grants to Fund up to 75% of 5-Year Costs	23/01/23
Hemostemix Announces Letter of Commitment For $250,000 of Funding by McGill University Health Centre Foundation	19/01/23
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	29/11/22
Hemostemix Inc. Announces Evolution of Patented Automated Cell Therapy System	15/11/22
Hemostemix Inc. Announces Exploring Clinical Trial Financing Alternatives	05/10/22
Hemostemix Inc. Appoints Ernst von Schwarz to its Scientific Advisory Board	27/09/22
Hemostemix Inc. Announces the Appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board	21/09/22
Hemostemix Announces Appointment to Scientific Advisory Board	20/09/22
Hemostemix Announces Appointment of Nadia Giannetti, MD, to its Scientific Advisory Board	16/09/22
Hemostemix Inc. Appoints Nadia Giannetti to its Scientific Advisory Board	16/09/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Hemostemix Inc.

Equities

HEM

CA4236943060

Other languages

Filters